Incidence, Management Patterns, and Outcomes of Cardiovascular Implantable Electronic Device-Related Infection – A Retrospective Registry-Based Analysis
Authors:
- Pravin K. GoelPGPravin K. Goel
- Paritosh RajputPRParitosh Rajput
- Ankit Kumar SahuASAnkit Kumar Sahu
- Roopali KhannaRKRoopali Khanna
- Naveen GargNGNaveen Garg
- Satyendra TewariSTSatyendra Tewari
- Sudeep KumarSKSudeep Kumar
- Aditya KapoorAKAditya Kapoor
Open Access
- 1 October 2022
- journal article
- Published by Medknow in Journal of Indian College of Cardiology
- Vol. 12 (4) , 156-161
Abstract
Introduction: Cardiovascular implantable electronic device (CIED) infection contributes to a significant clinical and financial burden. We sought to assess CIED postimplant infection rates and the effect of different treatment modalities on reinfection over a long-term follow-up. Methods: We retrospectively analyzed CIED recipients presenting with complications during 2010–2019 at our center. Data related to the different management modalities used as per the discretion of treating physician, were collected and patients were followed up telephonically. Results: A total of 3394 patients underwent CIED implantation of which 122 (3.5%) patients developing complications were included in the study. Mean age of the patients was 66.4 ± 12.5 years. Single-chamber ventricular pacing (VVI), dual-chamber (DDD) pacing, and biventricular pacing were seen in 68 (56.2%), 51 (41%), and 3 (2.8%) patients, respectively. CIED infection was seen in 61 patients (1.8%). Strategies used for CIED infection management included: new device implantation on contralateral side (n = 34; 55.7%), old device repositioning on same side (n = 14; 22.8%), antibiotic therapy alone (n = 5; 8.5%), resterilized device implantation on contralateral side (n = 3; 4.9%), epicardial lead placement (n = 3; 4.9%), and permanent device removal (n = 2; 3.3%). The CIED reinfection rates for the above strategies were 2.9%, 71.4%, 80%, 100%, 0% and 0%, respectively. Conclusion: Multiple strategies are being used in real-world practice for the management of CIED infection. Previously advocated strategy of reimplanting resterilized CIED is associated with high recurrence rates. The best practice still remains to implant a new device on the contralateral side post extraction of infected hardware.Keywords
This publication has 9 references indexed in Scilit:
- Infections Associated with Resterilized Pacemakers and DefibrillatorsNew England Journal of Medicine, 2020
- European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections—endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)EP Europace, 2019
- Cardiac device infections are associated with a significant mortality riskHeart Rhythm, 2012
- Cardiovascular Implantable Electronic Device Replacement Infections and Prevention: Results from the REPLACE RegistryPacing and Clinical Electrophysiology, 2011
- Transvenous Lead Extraction: Heart Rhythm Society Expert Consensus on Facilities, Training, Indications, and Patient ManagementHeart Rhythm, 2009
- Management and Outcome of Permanent Pacemaker and Implantable Cardioverter-Defibrillator InfectionsJACC, 2007
- Rising Rates of Cardiac Rhythm Management Device Infections in the United States: 1996 through 2003JACC, 2006
- One Stage Side‐to‐Side Replacement of Infected Pulse Generators and LeadsPacing and Clinical Electrophysiology, 2006
- Management of the Infected Pacemaker: Explantation, Sterilization, and ReimplantationThe Annals of Thoracic Surgery, 1985